What is ACAD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.41B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ACAD?

P/E (TTM) is 8.96 and 52-week range is $19.32 to $30.96 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ACAD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ACAD?

The company profile lists revenue (TTM) near $1.13B, net income (TTM) near $377M, EPS (TTM) near $2.21 when available from the market-data feed. Figures are informational and may lag live markets.

Where is ACADIA Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 171.2M shares outstanding, ISIN US0042251084 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

ACADIA Pharmaceuticals Inc

$ACAD

Health Care · Biotechnology

IR Run Scenarios

$19.78

+1.02%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 796 full-time employees. The company went IPO on 2004-05-27. The firm is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. The company is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Employees

797

Website

acadia.com/

IPO

2004-05-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)